Vaccines Market Size is Projected to Jump USD 55.2 Billion by 2026
The global Vaccines Market size is anticipated to around USD 55.2 billion by 2026, this market is anticipated to grow with 6.4% CAGR during the forecast time period.
North America accounted for the largest share of the vaccines market in 2018 and is anticipated to maintain its dominance during the forecast period. More awareness about vaccination schedule, favorable reimbursement, presence of major market players, and supportive government regulations to increase vaccination among new born and high risk people are the major factors for the dominance of the region. Although number of vaccination in developing countries is greater than that of industrialized countries. However, amount spent on vaccination by the government and individuals is more than developing regions. Asia Pacific is expected to observe the fastest growth during the forecast period. Investment by market players due to availability of opportunities, government support, and increasing awareness among people about vaccination are likely to propel the market growth in Asia Pacific. For instance, in September 2019, Serum Institute of India opened the world's largest vaccine manufacturing facility in India. The facility is getting ready to export its vaccines to most regulated markets such as the U.S. and Europe. Hence, investment by market players in this region is a key factor for the significant growth in the coming years.
Based on technology, the vaccines market has been segmented into inactivated vaccines, conjugate vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines. The conjugate vaccine segment held the largest share in the market due to long lasting protection and greater ability to give protection to toddlers and infants. Conjugate vaccine has a combination of weak and strong antigen as a carrier so that immune system gives strong response to weak antigen.
Free Download Sample Report Pages for Better understanding@ https://www.acumenresearchandconsulting.com/request-sample/1599
Pediatric vaccines accounted for the maximum share of the market in 2018. This can be attributed to large targeted population, government initiatives to increase children vaccination, and increasing awareness about vaccination schedules. Adult vaccine segment is also expecting significant growth in coming years due to rising awareness about regular health check up and vaccination after 40 years of age.
Based on the route of administration, the market has been segmented into intramuscular & subcutaneous, oral, and others. Intramuscular accounted for the maximum share of the market in 2018 and is expected to maintain its dominance during the forecasts period as the route avoid adverse local effect of vaccine.
High development cost and stringent government regulations for the approval and commercialization of product are likely to restrain the market growth during the forecast period.
The vaccine market is highly fragmented in nature with presence of big giant to small regional players. Key players operating in the vaccines market are Astellas Pharma Inc.; Bavarian Nordic; CSL Limited; Daiichi Sankyo Company, Limited; Emergent BioSolutions, Inc.; GlaxoSmithKline plc; Johnson & Johnson; MedImmune, LLC; Merck & Co., Inc.; Mitsubishi Tanabe Pharma Corporation. Research & development activities and mergers & acquisitions to broaden the product portfolio and geographical reach have been the most adopted strategies by market players to enhance their market share.
View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/vaccines-market
Vaccines Market By Technology (Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines), By Indication (Dengue, DTP, Hepatitis, HPV, Influenza, Meningococcal, MMR, Pneumococcal, Polio, Rotavirus, Varicella) By Type(Monovalent, Multivalent) By Route of Administration(Intramuscular, Subcutaneous, Oral, Others) By Type of Patient(Children, Adult) - Global Industry Analysis, Market Size, Opportunities And Forecast, 2019 - 2026
Some of the key observations regarding vaccine industry include:
- In April 2019, the first malaria vaccine, RTS'S, launched in Malawi, Africa. In Africa, more than 250,000 children die due to malaria every year. Hence, with the help of World Health Organization (WHO) and regional government bodies, RTS,S, was launched in the Africa.
- In March 2019, Elicio Therapeutics, a U.S. based immuno-oncology company, launched with financial backing to treat a range of cancers. The company is developing immune-stimulators, precision vaccines, and cellular therapies.
- In February 2019, Bharat Biotech acquired Chiron Behring Vaccines Pvt. Ltd. from GlaxoSmithKline Asia. Chiron is one of the largest manufactures of rabies vaccines across the world. The acquisition is helping Bharat biotech to strengthen its product portfolio.
- In October 2018, Emergent BioSolutions Inc. acquired PaxVax, a specialty vaccines company that protects from a range of emerging and existing infectious diseases. With acquisition Emergent expanded its sales capacity and product portfolio with addition of two major vaccines Vivotif (Typhoid vaccine) and Vaxchora (Cholera vaccine).
- In August 2017, Sanofi acquired Protein Sciences, a vaccine company based in the U.S. through this acquisition Sanofi added promising product to its influenza vaccine product portfolio. Flublok is the only U.S. FDA approved recombinant influenza vaccine with protein based.
Market Segmentation
Market By Technology
- Conjugate Vaccines
- Inactivated Vaccines
- Live Attenuated Vaccines,
- Toxoid Vaccines
- Recombinant Vaccines
By Indication
- Dengue
- DTP
- Hepatitis
- HPV
- Influenza
- Meningococcal
- MMR
- Pneumococcal
- Polio
- Rotavirus
- Varicella
By Type
- Monovalent
- Multivalent
By Route of Administration
- Intramuscular
- Subcutaneous
- Oral
- Others
By Type of Patient
- Children
- Adult
Market By Geography
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Key Questions Answered in the Report
The report addresses key questions concerning the market evolution and overarching trends shaping global market growth. Some of the key questions answered in the report include-
- What is the overall structure of the market?
- What was the historical value and what is the forecasted value of the market?
- What are the key product level trends in the market?
- What are the market level trends in the market?
- Which of the market players are leading and what are their key differential strategies to retain their stronghold?
- Which are the most lucrative regions in the market space?
Request for Customization@ https://www.acumenresearchandconsulting.com/request-customization/1599
TABLE OF CONTENT
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Vaccine
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Vaccine Market By Technology
1.2.2.1. Global Vaccine Market Revenue and Growth Rate Comparison By Technology (2015-2026)
1.2.2.2. Global Vaccine Market Revenue Share By Technology in 2017
1.2.2.3. Conjugate Vaccines
1.2.2.4. Inactivated Vaccines
1.2.2.5. Live Attenuated Vaccines
1.2.2.6. Toxoid Vaccines
1.2.2.7. Recombinant Vaccines
1.2.3. Vaccine Market By Indication
1.2.3.1. Global Vaccine Market Revenue and Growth Rate Comparison By Indication (2015-2026)
1.2.3.2. Global Vaccine Market Revenue Share By Indication in 2017
1.2.3.3. Dengue
1.2.3.4. DTP
1.2.3.5. Hepatitis
1.2.3.6. HPV
1.2.3.7. Influenza
1.2.3.8. Meningococcal
1.2.3.9. MMR
1.2.3.10. Pneumococcal
1.2.3.11. Polio
1.2.3.12. Rotavirus
1.2.3.13. Varicella
1.2.4. Vaccine Market By Type
1.2.4.1. Global Vaccine Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.4.2. Global Vaccine Market Revenue Share By Type in 2017
1.2.4.3. Monovalent
1.2.4.4. Multivalent
1.2.5. Vaccine Market By Route of Administration
1.2.5.1. Global Vaccine Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
1.2.5.2. Global Vaccine Market Revenue Share By Route of Administration in 2017
1.2.5.3. Intramuscular
1.2.5.4. Subcutaneous
1.2.5.5. Oral
1.2.5.6. Others
1.2.6. Vaccine Market By Type of Patient
1.2.6.1. Global Vaccine Market Revenue and Growth Rate Comparison By Type of Patient (2015-2026)
1.2.6.2. Global Vaccine Market Revenue Share By Type of Patient in 2017
1.2.6.3. Children
1.2.6.4. Adult
1.2.7. Vaccine Market By Geography
1.2.7.1. Global Vaccine Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.7.2. North America Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.3. Europe Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.4. Asia-Pacific Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.5. Latin America Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.6. Middle East and Africa (MEA) Vaccine Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Vaccine Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Vaccine Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Vaccine Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Vaccine Major Manufacturers in 2017
CHAPTER 4. Vaccine Market By Technology
4.1. Global Vaccine Revenue By Technology
4.2. Conjugate Vaccines
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Inactivated Vaccines
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Live Attenuated Vaccines
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Toxoid Vaccines
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Recombinant Vaccines
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. Vaccine Market By Indication
5.1. Global Vaccine Revenue By Indication
5.2. Dengue
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. DTP
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Hepatitis
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. HPV
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Influenza
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.7. Meningococcal
5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.8. MMR
5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.9. Pneumococcal
5.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.10. Polio
5.10.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.10.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.11. Rotavirus
5.11.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.11.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.12. Varicella
5.12.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.12.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. Vaccine Market By Type
6.1. Global Vaccine Revenue By Type
6.2. Monovalent
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Multivalent
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. Vaccine Market By Route of Administration
7.1. Global Vaccine Revenue By Route of Administration
7.2. Intramuscular
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Subcutaneous
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Oral
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.5. Others
7.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 8. Vaccine Market By Type of Patient
8.1. Global Vaccine Revenue By Type of Patient
8.2. Children
8.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
8.3. Adult
8.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 9. North America Vaccine Market By Country
9.1. North America Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. North America Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. U.S.
9.3.1. U.S. Vaccine Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.4. Canada
9.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 10. Europe Vaccine Market By Country
10.1. Europe Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Europe Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. UK
10.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.4. Germany
10.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.5. France
10.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.6. Spain
10.6.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.7. Rest of Europe
10.7.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 11. Asia-Pacific Vaccine Market By Country
11.1. Asia-Pacific Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Asia-Pacific Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. China
11.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.4. Japan
11.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.5. India
11.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.6. Australia
11.6.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.6.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.7. South Korea
11.7.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.7.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.8. Rest of Asia-Pacific
11.8.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.8.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 12. Latin America Vaccine Market By Country
12.1. Latin America Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Latin America Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Brazil
12.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.4. Mexico
12.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.5. Rest of Latin America
12.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 13. MIDDLE EAST & AFRICA VACCINE MARKET BY COUNTRY
13.1. Middle East & Africa Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Middle East & Africa Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. GCC
13.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.4. South Africa
13.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.5. Rest of Middle East & Africa
13.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 14. COMPANY PROFILE
14.1. Astellas Pharma Inc.
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Bavarian Nordic
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. CSL Limited
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. Daiichi Sankyo Company, Limited
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Emergent BioSolutions, Inc.
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. GlaxoSmithKline plc
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Johnson & Johnson
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. MedImmune, LLC
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. Merck & Co., Inc.
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies
14.10. Mitsubishi Tanabe Pharma Corporation
14.10.1. Company Snapshot
14.10.2. Overview
14.10.3. Financial Overview
14.10.4. Product Portfolio
14.10.5. Key Developments
14.10.6. Strategies
14.11. Others
14.11.1. Company Snapshot
14.11.2. Overview
14.11.3. Financial Overview
14.11.4. Product Portfolio
14.11.5. Key Developments
14.11.6. Strategies
CHAPTER 15. RESEARCH APPROACH
15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope The report is readily available and can be dispatched immediately after payment confirmation.
Buy this premium research report – https://www.acumenresearchandconsulting.com/buy-now/0/1599
If you would like to place an order or have any questions, please feel free to contact at [email protected] | +1-407-915-4157 OR +1-408-900-9135
About Acumen Research and Consulting:
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.
Contact Us:
Phone: +14079154157 | +14089009135